News Headlines

31. Merck To Acquire ArQule, Advancing Leadership In Oncology 12/9/2019

    Merck known as MSD outside the United States and Canada, and ArQule, Inc. today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire ArQule for $20 per share in cash for an approximate total equity value of $2.7B.

32. Sanofi To Acquire Synthorx To Bolster Its Immuno-Oncology Pipeline For $2.5B 12/9/2019

    Sanofi and Synthorx, Inc. (NASDAQ: THOR), a clinical-stage biotechnology company focused on prolonging and improving the lives of people suffering from cancer and autoimmune disorders, entered into a definitive agreement under which Sanofi will acquire all of the outstanding shares of Synthorx for $68 per share in cash, which represents an aggregate equity value of approximately $2.5 billion (on a fully diluted basis).

33. Autoimmune Technologies Announces New Subsidiary To Develop Novel Antibody And Allogeneic Somatic Stem Cell Therapeutics For The Treatment Of Invasive Candidiasis And Other Infectious Disease 12/9/2019

    Autoimmune Technologies LLC, a biotechnology company developing diagnostics and therapies for non-infectious and infectious disease, has established a new subsidiary, Stadius Biopharma LLC, to focus on proprietary anti-infective antibody therapeutics for diseases that are inadequately addressed by current standard-of-care medicines.

34. Thermo Fisher Scientific Opens $90 Million Viral Vector Manufacturing Site in Massachusetts 12/5/2019

    New facility will create 200 new jobs and accelerate commercialization of gene and cell therapies.

35. Fujifilm Establishes The Bio Science & Engineering Laboratories U.S.A. To Start Full-Scale Translational Research For Biotherapeutics In The United States 12/5/2019

    FUJIFILM Corporation (President: Kenji Sukeno) announced that it has begun full-scale research activities to advance the field of translational research for biotherapeutics at its newly established “Bio Science & Engineering Laboratories U.S.A.”

36. PCI Pharma Services Completes Expansion Of Its Specialty Drug Product Capabilities At Rockford, IL Site 12/4/2019

    PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global outsourcing solutions provider, today announced the completion of an expansion to its Rockford, IL facility to enhance its Specialty Drug Product Capabilities.

37. AWS Announces Strategic Collaboration With Novartis To Accelerate Digital Transformation Of Its Business Operations 12/4/2019

    Today, Amazon Web Services, Inc. (AWS), an Amazon.com company (NASDAQ: AMZN), announced a multi-year strategic collaboration with Novartis to reimagine this leading pharmaceutical company’s core pharmaceutical manufacturing, supply chain, and delivery operations using AWS’s portfolio of cloud services.

38. VGXI Selects BE&K As Design Firm For New 240,000 Square Foot Manufacturing Facility 12/3/2019

    VGXI, a highly regarded CDMO supporting the gene therapy and DNA vaccine industries, announces it has chosen the integrated construction services company BE&K Building Group as Design-Build Partner for the initial phase of its new manufacturing site.

39. Boehringer Ingelheim Chooses NiceLabel Solution To Help Support Standardized Labeling Worldwide 12/2/2019

    Global pharmaceutical company, Boehringer Ingelheim, has selected NiceLabel, a leading global developer of label design software and label management systems, to help it create a global standardized labeling process.

40. Astellas Buys Audentes Therapeutics For $3B For Gene Therapy Drug Manufacturing Expansion 12/2/2019

    Astellas Pharma Inc. (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) and Audentes Therapeutics, Inc. (Chairman and CEO: Matthew R. Patterson, “Audentes”), today announced that they have entered into a definitive agreement for Astellas to acquire Audentes at a price of US$60.00 per share in cash, representing a total equity value of approximately US$3B.